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Antibiotic use drives the spread of antibiotic re-sistance. A considerable proportion of antibi-
otic prescriptions are prescribed unnecessarily for 
conditions that are either self-limiting or nonbacte-
rial in etiology (1
inappropriately with antibiotics, expanding access 
of reducing unnecessary prescribing and preventing 
resistant infections (2).
In 2013, England and Wales began rolling out 
2–16-year-old children (3). Here, we estimate the 




tations lead to antibiotic prescriptions. Our age-strat-
the driver of resistance, because hospitalizations for 
4).
-
tation rate, we used a previous time-series statis-
 
seasons in the United Kingdom (5), yielding a 
-
years (Table 1). For our uncertainty analysis (Ap-
pendix Table, https://wwwnc.cdc.gov/EID/
article/25/12/19-1110- App1.pdf), we used a lower 
estimate of 11.8 per 1,000, from a longitudinal study 
6), 
and a higher estimate of 21.4 per 1,000, from a time-
seasons in England and Wales (4).
We estimated that 726 antibiotic prescriptions 
5). For our uncertainty analysis, 
we used a lower estimate of 313 per 1,000, derived 
from electronic health records of prescriptions 
like illness (ILI) or acute cough in England during 
2013–2015 (7).
We assumed that LAIV prevents 49% of symp-
-
ly published mathematical model of pediatric LAIV in 
England and Wales, which assumes 50% uptake and 
either 70% (matched-year) or 42% (unmatched-year) 
3). This reduction is 
consistent with a pilot study comparing consulta-
tion rates in treatment with control areas before and 
after LAIV rollout (8). For our uncertainty analysis, 
we used lower and higher estimates of 32% and 63% 
an uptake of 30% and 70%, respectively.
unnecessary prescribing, we used linear regression 
with a country’s rate of primary-care antibiotic use 
as the predictor variable and previously published 
2015 estimates of adverse health outcomes associated 
with 16 resistant bacterial strains across European 
countries (9) as the response variables. We adopted a 
Vaccination on Antibiotic 
Resistance, England and Wales
1 1
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DISPATCHES
Vaccines against viral infections have been proposed 
to reduce prescribing of antibiotics and thereby help 
control resistant bacterial infections. However, by com-
bining published data sources, we predict that pedi-
and Wales will not substantially reduce antibiotic con-
sumption or adverse health outcomes associated with 
antibiotic resistance.
Scotland, UK (K.E. Atkins)
1These authors contributed equally to this article.
published cost estimate of $1,415 per resistant infec-
tion (2016 USD) (10 -
We used Monte Carlo sampling to explore un-
certainty across estimates for consultation rate, pre-
scribing rate, and LAIV effectiveness, weighting age 
groups by using 2015 demographic data for England 
and Wales. (Analysis code and data at http://github.
com/nicholasdavies/laiv_amr_ew; additional details 
in the Appendix.)
We found that pediatric LAIV has the potential 




















0–6 mo – – – – – –
6 m–4 y – – –9.64) –16.1) – –
–14 y – – – 9.11 (6.48–11.8) – –12.8)
–44 y 12.8 (10.2– –0.814) – – – –
–64 y 12.4 (9.84–14.9) – – – –0.484) 4.22 (2.90–
> – – – – – –6.68)
Overall – – – –12.9) 0.494 (0.446– –
–
†Per 1,000 person-years in England and Wales.
‡Reduction in antibiotic prescriptions among vaccinees per 1,000 vaccine recipients, not accounting for herd immunity, presented separately for 
unmatched and matched seasons.
–16 years of age, accounting for herd immunity.
¶Per 1,000 person-years in England and Wales, accounting for herd immunity.
Figure 1. Estimated incidence 
of adverse health outcomes 
resulting from antibiotic-
resistant infections, plotted 
against the overall antibiotic 
consumption in primary care 
resistant cases/1,000-
person-years; B) attributable 
indicate datapoints for the 
United Kingdom; error bars 
indicate linear regressions; 
density interval [HDI] 3.7–7.0) prescriptions per 1,000 
person-years (Table 1) across the population of Eng-
land and Wales, or 0.8% of the antibiotic dispensation 
rate for primary care in England and Wales in 2015. 
For comparison with secular trends, this rate has fallen 
by 2.5% each year during 2012–2018 in England (Ap-
pendix Figure). Focusing on vaccine recipients only, 
we estimated that the direct effectiveness of LAIV on 
antibiotic consumption is 5.8 (95% HDI 4.1–7.5) fewer 
prescriptions per 1,000 person-years in unmatched 
years and 9.9 (95% HDI 7.0–13) in matched years.
Although 0.8% is a small decrease in antibiotic 
use, it might appreciably improve the cost-effec-
tiveness of pediatric LAIV if the healthcare costs 
of resistance are substantial enough (Figure 1). We 
estimated that LAIV has the potential to reduce 
resistance-attributable disability-adjusted life years 
(DALYs) by 642, cases by 432, and deaths by 22 per 
year in England and Wales (Table 2); averted DALYs 
were spread relatively evenly across the 7 causative 
pathogens analyzed (Figure 2, panel A). We esti-
mated a yearly cost saving of £224,000 for averted 
resistant infections. Compared with the projected 
incremental cost (program cost minus healthcare 
saving) of pediatric LAIV at £63.6 million, and its 
projected effect of saving 27,475 quality-adjusted life 
years and averting 799 deaths yearly (3), accounting 
for resistance will not substantially increase the cost-
effectiveness of pediatric LAIV in this setting. Our 
over the effect of LAIV on resistance-associated ad-
verse health outcomes.
Conclusions
Our estimates for the foreseeable reduction in an-
tibiotic prescribing from the LAIV program in 
England and Wales might seem surprisingly low, 
given that sore throat, cough, and sinusitis together 
account for 53% of all inappropriate prescribing, 
which in turn accounts for at least 9%–23% of all 
prescribing in England (1). However, many viral 
and bacterial pathogens cause these symptoms. By 
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Table 2.
outcomes associated with antibiotic resistance, England and 
Wales*
Outcome England and Wales





live attenuated influenza vaccine.
Figure 2.
attributable to antibiotic-resistant bacterial strains, England and 
potential reductions are highlighted in black and reported 
next to each bar. B) One-way uncertainty analysis, showing 
prescribing per general practitioner consultation, and how the 
-
sultations for acute respiratory illness in England 
(4
vaccination to substantially reduce antibiotic use in 
this setting.
Our base-case estimate of 726 antibiotic pre-
-
tations is more than double what electronic health 
records suggest (7). One explanation is that our 
estimate, derived from statistical attribution of an-
-
ing 1995–2009 (5), feasibly includes prescribing for 
secondary infections such as otitis media, sinusitis, 
and pneumonia. Moreover, electronic health records 
recorded (6). Conversely, antibiotic use in England 
has declined since 1995 (by 22% during 1998–2016) 
(11). Accordingly, our base-case results should be 
interpreted as the maximum potential reduction by 
LAIV of antibiotic use.
-
za vaccines on vaccinated children has ranged from a 
44% reduction (Italy) to a 6% increase (United States) 
in antibiotic prescriptions over the 4-month period 
following vaccination, whereas estimates of the ef-
fect over entire populations (all ages, vaccinated 
and unvaccinated) range from 11.3 fewer prescrip-
tions per 1,000 person-years in Ontario, Canada, to 
3.9 fewer in South Africa and Senegal (Appendix). 
This variability might arise from differences in vac-
-
otic use, which make generalizing estimates across 
settings challenging.
The adverse health outcome estimates that we 
adopt (9) assume that resistant infections add to, rath-
assumption would further reduce the projected effect 
of LAIV, because some prevented resistant infections 
would be replaced by nonresistant infections (12).
vaccination on antibiotic resistance by using the re-
-
otic use in England and Wales, and can be adapted 
to other settings for which this relationship can be 
-
lation, directly with antibiotic use. Challenges with 
that approach include appropriately controlling for 
confounding factors in the relationship between 
vaccine uptake and antibiotic use and quantifying 
herd immunity. However, consistent with our 
suggested little or no effect of LAIV uptake on pre-
scribing: a self-controlled case-series study found 
that 2–4-year-old LAIV recipients took 13.5% fewer 
amoxicillin courses in the 6 months after vaccina-
tion (13), whereas an LAIV pilot study detected no 
difference in prescribing rates for respiratory tract 
infections between treatment groups (14). No single 
vaccine is likely to substantially reduce inappropri-
ate antibiotic use in the United Kingdom.
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